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The paper presents the development of a “proof-of-principle” hands-free and self-contained diagnostic platform for detection
of human papillomavirus (HPV) E6/E7 mRNA in clinical specimens. The automated platform performs chip-based sample
preconcentration, nucleic acid extraction, ampliﬁcation, and real-time ﬂuorescent detection with minimal user interfacing. It
consists of two modular prototypes, one for sample preparation and one for ampliﬁcation and detection; however, a common
interface is available to facilitate later integration into one single module. Nucleic acid extracts (n = 28) from cervical cytology
specimens extracted on the sample preparation chip were tested using the PreTect HPV-Proofer and achieved an overall detection
rate for HPV across all dilutions of 50%–85.7%. A subset of 6 clinical samples extracted on the sample preparation chip module
was chosen for complete validation on the NASBA chip module. For 4 of the samples, a 100% ampliﬁcation for HPV 16 or 33 was
obtained at the 1:10 dilution for microﬂuidic channels that ﬁlled correctly. The modules of a “sample-in, answer-out” diagnostic
platform have been demonstrated from clinical sample input through sample preparation, ampliﬁcation and ﬁnal detection.
1.Introduction
Over the past decade, in a drive towards automation of
laboratory testing, there has been considerable interest in de-
veloping more sensitive and speciﬁc molecular diagnostics
with reduced time to result, in a way that is cost eﬀective,
requires minimal manual handling, and can be performed in
a low-resource setting. In a recent review of “point-of-care”
(POC) technologies, it was concluded that the most promis-
ing technology which fulﬁls this need is based on microﬂu-
idics, as it has the potential to control both the complex ﬂu
idic handling required during sample processing and the rea2 Journal of Oncology
gent mixing for nucleic acid ampliﬁcation, in areas which
are separated spatially and temporally, while being com-
patible with inexpensive materials and fabrication methods
[1]. Microﬂuidic approaches in diagnostics achieve signif-
icant reagent volume reduction and thus cost-drive innova-
tion, potentially achieving widespread penetration in non-
hospital, non-specialised environments. However, microﬂu-
idic approaches are not without their challenges [2]. The
ﬁeldof“lab-on-a-chip”(LOC)diagnosticshasgrownrapidly
from this basic need, and it is fast accelerating towards a
“sample-in answer-out” platform for molecular diagnostics.
A number of reviews have explored the potential use of LOC
technology in areas such as clinical diagnostics, personalized
medicine, global health, and forensics [1, 3–8].
While the level of complexity of LOC devices varies,
the development of “sample-in and answer-out”, multifunc-
tional, integrated LOC platforms is not beyond reach. Such a
device which would facilitate the transfer of POC diagnostics
to the near patient setting would have multiple positive out
comes for patient care. The potential introduction of POC-
LOC technology to the doctor’s oﬃce could dramatically
reduce the time-to-result, facilitating early disease interven-
tion and reduced patient anxiety. As generic nucleic acid
technology can be adapted to a wide range of tests, a
nucleicacid-basedPOC-LOCapproachmayfacilitateamore
complete and accurate diagnosis: however, it is not without
itschallenges,inparticular,itmustaccountfortheenormous
variation in source clinical material to obtain a valid result
while also accounting for the heterogeneity that exists within
a clinical sample type cohort.
The technology platform presented herein uses human
papillomavirus (HPV) mRNA detection from cervical liq-
uid-based cytology specimens as a model system. HPV is the
oncogenic viral factor in cervical cancer [9]. Published data
show that the incidence of cervical cancer is much higher in
low-income countries than high-income countries [10]. As
much as 83% of the cervical cancers occur in developing
countries, which counts for 15% of female cancers. In de-
veloped countries, cervical cancer accounts for only 3.6%
of new cancers. The mortality rates for cervical cancer are
considerably lower than incidence as cervical cancer is highly
preventable through cytological screening programs that
facilitatethedetectionandtreatmentofprecancerouslesions.
Well-developed screening programs, especially in high-in-
come areas, have contributed to a substantial decline for
cervical cancer incidence and mortality. Introducing a plat-
form as presented in this work for screening of precancerous
lesionscombinedwitheﬀectivetreatment(testandtreatpos-
sibilities)inlow-incomecountrieshasenormouspotentialto
reduce the mortality rate in these areas in the world [10, 11].
The LOC modules described in this study comprises two
distinct microﬂuidic chips with their associated supporting
technologies, one for sample preparation and the other for
nucleic acid ampliﬁcation. At present, the modules may be
used in tandem and will eventually be integrated together,
achieving the “sample-in, answer-out” approach (Figure 1).
Nucleic acid sequence-based ampliﬁcation (NASBA) [12]
technology with real-time ﬂuorescence measurement was
adapted to detect HPV mRNA in cervical specimens and
cervical cell lines. The isothermal nature of NASBA greatly
simpliﬁes ampliﬁcation strategies for nucleic acid detection
on chip. This platform has huge potential within POC diag-
nostics as up to 16 diﬀerent targets can be detected simulta
neously for each clinical sample analysed. We present de-
tailed information in relation to NASBA chip construction,
microﬂuidics and results on analysis of cell line and clinical
samples with the devices. We adopted an iterative approach
tothechipdevelopment andoptimisation ofchemistriesand
assays and have used an industry gold standard (PreTect
HPV-Proofer, NorChip AS, Norway) for HPV E6/E7 mRNA
detectiontocompareourresults.ThestandardPreTectHPV-
Proofer was used to (a) determine the initial HPV status of
the samples/cell lines and (b) to analyse the quality of the
nucleic acid extract from the sample prep-aration chip. We
outline some of the challenges involved in the creation of a
fully integrated “sample-in and answer-out” LOC system.
2.MaterialsandMethods
2.1. Cell Lines and Clinical Specimens. For optimisation of
both the sample preparation and the NASBA chip, total
nucleic acid (TNA) extracted using the NucliSENS easyMAG
instrument (bioMeri´ eux, France), from CaSki and SiHa cer-
vical cancer cell lines obtained from the American Type
Culture Collection (ATCC) were used. Nucleic acids were ex-
tracted from cell pellets containing 50,000–5 cell/mL [13].
For clinical evaluation, cervical smear specimens collected in
PreservCyt, (Hologic Inc. Bedford, Mass, USA) and PreTect
TM (NorChip AS, Norway) were used. Specimens with high-
grade cervical intraepithelial neoplasia were chosen for
“proof of principle” experiments. For gold standard HPV
tests, total nucleic acid were extracted from 5mL clinical
PreservCyt specimen on Qiagen M48 BioRobot and eluted
in 50µL. The baseline HPV mRNA status of specimens was
determined for the 5 high-risk HPV types (HPV16, 18, 31,
33, and 45) and internal housekeeping control (U1A) using
PreTect HPV-Proofer [11, 14–19]. Ethical approval for the
study was obtained from the Research Ethics Committee
at the Coombe Women and Infants University Hospital,
Dublin, Ireland and the South African Ethics Committee at
Pretoria Academic Hospital, Pretoria, South Africa.
2.2. Sample Preparation Chip. Cell lines and clinical speci-
menswereextractedonasamplepreparationplatformwhich
has been previously described elsewhere [13]. The sample
preparation system is capable of performing total sample
preparation and automated extraction of nucleic acids
from human clinical specimens ﬁxed in a methanol-based
solution.
All necessary reagents for cell lysis, washing, and elution
are stored on chip and the extraction is performed in 2 ﬁlter
stages:oneforcellpreconcentrationandtheotherfornucleic
acid capture. The chip consists of COC (cyclic oleﬁn copoly-
mer; Ticona COC-5013) sealed with COP (cyclic oleﬁn poly
mer; Zeon, Zeonor 1420R). All chips were fabricated by mill
ing into blank injection moulded chips of size 64mm ×
43mm × 3mm. After mounting of the ﬁlters, the chips were
s o l v e n tb o n d e dw i t ha1 0 0µm COP foil and three turningJournal of Oncology 3
3. Cell lysis
4. Nucleic acid extraction
5. Loading of puriﬁed nucleic
acid and mastermix
6. Sample metering into
8 channels
7. Dissolving of primers and
probe (reaction chamber 1)
8. Dissolving of enzymes and
start of reaction
(reaction chamber 2)
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Figure 1: Schematic approach to the development of an integrated LOC device for the detection of HPV nucleic acid (involving a nucleic
acid extraction chip and NASBA ampliﬁcation chip).
valves were mounted on the chip surface. A customised
design for the valve seals of the turning valves allows for the
selective connection of channels on the chip.
The sample preparation chip (Figure 2(a)) consists of a
sample inlet (1), cell ﬁlter (2), a silica phase extraction ﬁlter
(SPE) (3), nucleic acid extraction reagent storage chamber
(4A), storage chamber for DMSO and sorbitol (4B) turning
valves (5), waste outlet (6), sample outlet (7), and a pressure
sensor (8). For nucleic acid extraction, cells were collected
and concentrated on a ﬁlter (Buckmann GmbH & Co. KG,
Germany: Nylon, mesh width 10µm), where they were sub-
sequentlychemicallylysed[13].Thereleasednucleicacidwas
captured downstream onto a silica ﬁlter (Genomed GmbH,
Germany), in the presence of a chaotropic salt and extracted
by solid-phase extraction, using a modiﬁed Boom’s extrac-
tion method. Following extraction, downstream washing
steps were performed to remove cellular debris. Subsequent
air-dryingwascarriedoutbeforenucleicacidelution.Details
of the reagents for lysis, wash, and elution have been previ-
ously published [13].
2.3. Sample Preparation Instrument. T h es a m p l ep r e p a r a t i o n
instrument (Figure 2(b)) has been described previously [13].
Brieﬂy, it holds two modiﬁed syringe pumps containing two
syringes: one to pump 3mL sample through the cell capture
ﬁlter and a second one for ﬂuid actuation and drying by
pressurised air. The latter is connected to an external 3-
port/2way valve to allow for syringe reloading so that several4 Journal of Oncology
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Figure 2: Automated LOC system for sample preconcentration, nucleic acid extraction, ampliﬁcation, and real-time ﬂuorescent detection.
(a)Samplepreparationchip:sampleinlet[1],cellﬁlter[2],asilicaphaseextractionﬁlter[3],nucleicacidextractionreagentstoragechamber
[4A], storage chamber for DMSO and sorbitol [4B] turning valves [5], waste outlet [6], sample outlet [7], and a pressure sensor [8] (b)
Sample preparation instrument (c) NASBA chip: sample inlet [1], supply channel [2], metering channels [3], valve 1 [4A], valve 2 [4B],
valve 3 [4C], chamber 1 [5A], chamber 2 [5B], waste chamber [6], and instrument connection interface [7] (d) NASBA instrument.
piston strokes are possible, thus avoiding the need to draw
air through the chip. Fluid control is achieved through 3
turning valves which are connected to motors below the
chip holder table. A heater below the chip table elevates
the temperature during lysis and for drying of the SPE
ﬁlter before elution of nucleic acid. Custom built electronics
addressed by a LabVIEW program automatically control all
steps of operation from sample load to expulsion of the
puriﬁed nucleic acid.
2.4. NASBA Chip. The NASBA chip consists of a disposable
microﬂuidic cartridge composed of injection moulded COC
(Topas5013S-04fromTopasAdvancedPolymers,Germany).
The chips were manufactured by injection moulding using a
Battenfeld,EM50/120machine.Thechipconsistsofasample
inlet (1), a supply channel (cross-section of 400µm ×
200µm) (2), eight parallel reaction channels (3), 3 types of
hydrophobic valves (4A, 4B, 4C), reaction chamber 1 (5A),
reactionchamber2(5B),andawastechamber(6)containing
a highly absorbent ﬁlter paper (Figure 2(c)). Each of the
parallel reaction channels consist of three parts; a metering
channel (400µm × 120µm, volume of 740nL) and two mix-
ing/reaction chambers (volume approximately 800nL). The
two chambers and the metering channel are separated
by hydrophobically coated capillary valves of increasing
strength; the valve dimensions for the three valves 4A, 4B,
and 4C are 200µm × 80µm, 125µm × 80µm, and 50µm ×
50µm, respectively. Reaction chamber 2 serves as the real-
time ﬂuorescent detection chamber. The overall chip size is
75mm ×44mm ×1.5mm.Thechipsurfacewascoatedwith
a hydrophilic surface coating using 0.5% PEG (P2263, Sigma
Aldrich, Norway) in methanol. The hydrophobic valves
were coated with a mixture of 0.5% Teﬂon (Teﬂon AF 1600,
Du-Pont, Germany) and 0.25% carbon black (type 901,
Degussa, Germany) dissolved in perﬂuorinated solvent (Flu-
orinert FC-77, 3M, Germany) and spotted using a PipeJetJournal of Oncology 5
P9dispenser(BioFluidix,Germany)[20].Aftersurfacemod-
iﬁcation, a cotton linter ﬁlter (Schleicher & Schuell Bio-
Science GmbH, Germany) was placed in the waste chamber,
and the chips were manually sealed with polyoleﬁn sealing
foil containing microencapsulated glue on the contact side
(HJ Bioanalytik GmbH, Germany).
2.5. The NASBA Reagents. T h er e a g e n t su s e df o rN A S B A
chip reactions were obtained from the PreTect HPV- Proofer
assay with the addition of 0.013µg/µL BSA (Sigma Aldrich,
Germany) for NASBA ampliﬁcation. Premixed NASBA reac-
tion mixtures were mixed according to the manufacturer’s
instructions. In order to proceed to the incubation temper-
ature of 41◦C, a prepreparation step was required. For the
premixed reaction mixtures this involved incubating the
mastermixandpuriﬁednucleicacidsampletogetherat65◦C
for 2 minutes oﬀ chip. Subsequently, the temperature was
reduced to 41◦C and the enzyme was added to the reaction
mixture prior to loading onto the NABSA chip.
For some analyses performed on the NASBA chip,
rea-gent spotting on chip was conducted using the BioSpot
liq-uidhandlingplatform(BioFluidixGmbH,Germany)and
the PipeJet dispenser [21]. The aluminium chip holder was
cooled down to −80◦C prior to the spotting to ensure freez-
ingoftheNASBAreagentsuponimpactwithinthechambers
on chip. A volume of 125nL of enzyme solution including
2% PEG was dispensed in reaction chamber 2 and 250nL of
the primer/probe mix was dispensed into reaction chamber
1. The freeze-drying procedure was performed in a commer-
cial freeze-dryer (Triad, Labconco, USA). (The pa-
rameters for the freeze-drying procedure is described
in the supplementary information available online at doi:
10.1155/2012/905024.) In the prepreparation step for the
NASBA chips containing freeze-dried enzyme and prim-
er/probe mixes, only the remaining master mix reagents and
the puriﬁed nucleic acid were mixed and incubated oﬀ chip
at 65◦C for 2 minutes. The temperature was reduced to 41◦C
prior to loading the reaction mixture on chip.
T h er e a c t i o nv o l u m ef o rP r e T e c tH P V - P r o o f e rw a s2 0µL,
whilethereactionvolumeforNASBAonchipwas740nLper
reaction chamber.
2.6. The NASBA Instrument. Two versions of the NASBA
instrument were developed for this study. The Uniplex
Detector Version 1 of the instrument (Figure 2(d)) contains
an optical unit, which has one excitation wavelength and one
emission wavelength with the ability to detect HPV 16, 31,
and 33. The instrument comprises two major units: a system
for ﬂuidic actuation and control and an optical detection
unit.
The ﬂuidic activation mechanism is operated by a pres-
surepulsegenerationsystem,consistingofa500mLpressure
reservoir, three SMLD-5B valves from TechElan, a 0-1 PSID
pressure sensor (Honeywell, Norway) for system feedback
and a custom made syringe pump integrated into the in-
strument for pressure level adjustment. Sample heating and
temperature control of 41◦Ca n d6 5 ◦C are achieved by a
Peltier element (Marlow Industries, Sweden) and a ther-
mistor (Elfa, Norway) for feedback is located beneath the
chip surface. The accuracy of the heating system has been
determined to be better than 0.1◦C.
The optical detection unit consists of a ﬂuorescence exci-
tation detection module and a scanner. The scanner is a lin-
ear actuator (NEMA 17 linear actuator stepper motor
from Ultra motion) which scans across the chip, halting
above each reaction chamber to perform ﬂuorescent meas-
urements. The illumination ﬁbre is a 600µm core diameter
multimode ﬁbre with numerical aperture of 0.22 (Thorlabs,
Sweden). The detection ﬁbre is a 1000µm core diameter
multimode ﬁbre with numerical aperture of 0.48 (Edmund
Optics, UK). In the ﬁrst generation instrument, (Uniplex
Detector Version 1), a 1W blue LED from Luxeon was used
for excitation (excitation maximum wavelength 470nm),
and a band pass ﬁlter (Semrock, USA) was used to suppress
unwanted wavelengths. The instrument has since been
modiﬁed to include an additional amber LED (excitation
maximum wavelength 597nm) assessor (Luxeon) to facil-
itate multiple colour detection in the Multiplex Detector
Version 2. During operation, the LED is modulated with
a 310Hz square pulse train with 50% duty cycle. The sig-
nal is demodulated by a digital lock-in ampliﬁer, and
integrated for 1 second. The amount of light emitted from
the ﬁbre end is close to 10mW. At the detector side, two
lenses (Edmund Optics, UK) were used to limit the angular
cone through the emission ﬁlter (Semrock, USA). The mod-
iﬁed instrument has additional emission ﬁlters. A Multi-
Pixel Photon Counter (MPPC from Hamamatsu, Sweden)
was chosen to serve as detector of the ﬂuorescent signal.
Excitation maximum wavelengths for the two ﬂuorescent
colours used, FAM and ROX, are 494nm and 587nm, with
emission maximum wavelengths of 518nm and 607nm,
respectively.
In addition to the above-described components, the in-
strument contains custom made electronics. The control of
all instrument functions is performed via in-house software
developed in LabVIEW (National Instruments).
3. Results
The overall objective of the system is to develop a hands-free
diagnostic platform for detection of target nucleic acid in
clinical specimens. The automated platform presented here
performs chip-based sample preconcentration, nucleic acid
extraction, ampliﬁcation and real-time ﬂuorescent detection
with minimal user interfacing. It consists of two modular
prototypes, one for sample preparation and one for ampli-
ﬁcation and detection. The prototype instruments with their
associated disposable microfabricated chips (Figures 2(a)
and 2(c)) have been tested individually; however, a common
interface is available to facilitate later integration into one
single setup.
The sample preparation system is capable of performing
totalsamplepreparationandautomatedextractionofnucleic
acids from human clinical specimens ﬁxed in a methanol-
based solution. The automated sample preparation module
[13] and early work on the ampliﬁcation and detection
module [20, 22–24], are presented elsewhere. In this paper,
we present the combined sample preparation and detection6 Journal of Oncology
platform in a “proof of principle” study with particular
reference to testing from biological specimens and cell lines.
3.1. The Sample Preparation Chip and Instrument. This
s y s t e mh a sb e e nd e s c r i b e dp r e v i o u s l ya n dt e s t e do nc e l ll i n e s
[13]. In this paper, we demonstrate its utility in clinical
samples and its integration with the NASBA chip. Brieﬂy, the
cervical smear specimen was collected and concentrated on
a ﬁlter, where it was subsequently chemically lysed. The re-
leased nucleic acid was then captured further downstream
onto a silica ﬁlter in the presence of a chaotrophic salt solu-
tionandextractedbysolidphaseextractionusingavariantof
Boom’s method [25]. Several washing steps were performed
to remove the cell debris from the solid phase extraction
matrix and after air drying the puriﬁed nucleic acid is eluted.
Thenucleicacidextractedisthentransferredmanuallytothe
NASBA chip for ampliﬁcation and detection.
3.2.TheNASBAChipandInstrument. Nucleic acid extracted
on the sample preparation chip is mixed with master mix
and incubated at 65◦Co ﬀ chip, as described above. Initial
experiments were performed on the NASBA chip using
PreTect HPV-Proofer reagents premixed and added onto
the chip with the nucleic acid. A further development of
the NASBA chip involved freeze-drying primer/probes and
enzyme onto the chip. Data on this is presented below. The
mixture is loaded onto the chip inlet (Figure 2(c)), where it
spontaneously is drawn into the supply channel by capillary
forces. While the sample liquid ﬁlls the supply channel
towards the waste chamber, the parallel metering channels
are sequentially ﬁlled up to the position of the ﬁrst capillary
valve. When the sample reaches the waste chamber, it comes
into contact with the ﬁlter paper which starts to absorb
the liquid and hence acts as a capillary pump. The supply
c h a n n e li se ﬀectively drained, leaving a precisely metered
sample aliquot inside each of the metering channels. The
pressure pulse system of the instrument is then actuated,
transferringthesesampleplugsinparalleltotheﬁrstreaction
chamber. After a prescribed time, the pressure pulse system
is again actuated transferring the sample plugs to the second
reactionchamber,wherethereal-timeﬂuorescencedetection
isinitiated.Theshapeoftheampliﬁcationcurvegeneratedby
real-time increases in ﬂuorescence determines whether the
reaction is positive or not (Figure 3).
Sample metering was evaluated in terms of the number
of channels per chip successfully ﬁlled with sample during
the biochemical and ﬂuidic evaluations. The data is gathered
from clinical tests using premixed reagents described below.
In total, 16 chips were tested, corresponding to 128 metering
channels. Of these channels, 102 were successfully ﬁlled with
sample during the sample loading process, that is, a yield of
79.7%. Of the 16 chips tested, 6 were completely ﬁlled in all
8 channels.
Additionally, 9 NASBA chips were tested with freeze-
dried enzymes deposited in reaction chamber 2 or the
combination of freeze dried primer/probe mix deposited in
reaction chamber 1 and enzymes in reaction chamber 2. In
this case, 83.3% of the channels ﬁlled completely. Two chips
ﬁlled all 8 channels. The unsuccessful ﬁlling of 20.3% and
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Figure 3: (a) The ampliﬁcation plot of the clinical sample 508
(HPV 33, 1:10 dilution). All the 7 reaction chambers ﬁlled with
sampleareclassiﬁedaspositiveusingourinhousedataanalysiscode
alsousedintheconventionalPreTectAnalyserinstrument.Reaction
chamber number 8 was not ﬁlled with sample; hence, no increase
of ﬂuorescence was observed. The oﬀset of the curve is also lower
than the ﬁlled chambers, as the autoﬂuorescence of the reaction
mixture was not present. (b) Fluorescent micrograph of reaction
chambers (8–1) after ampliﬁcation of clinical sample 508 (HPV 33,
1:10 dilution). The air bubble located in reaction chamber number
4 contributes to the lower ﬂuorescent signal detected by the NASBA
instrument. No sample has entered reaction chamber 8.
16.7%ofthemeteringchannelsmaybeduetocloggingofthe
reaction channel, poor surface coating with PEG or Teﬂon
overﬂow into the metering channel from valve 1 during
spotting.
All on-chip ﬂow control is performed via a single chip-
to-world pressure interface. The chip and ﬂuidic control sys-
tem are designed such that the sample liquid is at no time
in contact with the instrument. All on-chip ﬂuidic control
is achieved by pressurized air via the ﬂuidic interface. In
this way, the risk of cross-contamination between samples is
avoided.
Flow actuation is achieved by generation of negative-
amplitude pressure pulses delivered to the downstream end
of the reaction channels via the connector block. During
operation, the syringe pump and the feedback pressure
sensor are used to set the desired pressure level in the reser-
voir. Once the correct pressure is reached, the sample plugs
are transferred via hydrophobic valves on chip.Journal of Oncology 7
Table 1: NASBA chip results on clinical specimens. Six clinical specimens extracted on the sample preparation platform were tested on the
NASBA chip platform for the dilutions 1:5 and 1:10. Positive ampliﬁcation of target is denoted with “+”, while a negative result is denoted
“−”. The table also shows the number of indeterminate reactions on chip, the number of channels ﬁlled and the overall ampliﬁcation
eﬃciency.
Sample NASBA chip
Clinical specimen ID HPV type Dilution of eluate + − Indeterminate No. channels ﬁlled Overall [% positive]
channels ﬁlled
478 HPV16 1:5 1 6 0 7 14
478 HPV16 1:10 0 7 0 7 0
479 HPV33 1:5 0 0 8 8 0
479 HPV33 1:10 8 0 0 8 100
508 HPV16 1:5 1 7 0 8 12.5
508 HPV16 1:10 0 0 0 0 0
508 HPV33 1:5 7 0 0 7 100
508 HPV33 1:10 7 0 0 7 100
511 HPV16 1:5 4 4 0 8 50
511 HPV16 1:10 6 2 0 8 75
520 HPV16 1:5 4 0 0 4 100
520 HPV16 1:10 5 0 0 5 100
522 HPV16 1:5 3 1 1 5 60
522 HPV16 1:10 8 0 0 8 100
522 HPV33 1:5 0 6 0 6 0
522 HPV33 1:10 0 6 0 6 0
In order to detect the reactions in eight parallel chambers
of the chip, the optical detection system consists of a ﬂuo-
rescence excitation/detection module and a scanner. The
scanning function is realized mechanically by introducing an
opticalprobeconnectedviaﬂexibleﬁbrestotheillumination
and detection source of the optical system. The probe
is attached to a linear actuator and scanned across the
chip, halting above each reaction chamber to perform the
necessary ﬂuorescence measurements. Two prototypes of the
NASBA instrument were produced. The main diﬀerence of
the two instruments is the optical features. The Uniplex
Detector Version 1 detects one ﬂuorescent colour, while the
Multiplex Detector Version 2 detects two ﬂuorescent colours.
3.3. “Proof of Principle”: The Sample Preparation Platform.
The preliminary sensitivity and speciﬁcity data for cell line
samples puriﬁed on the sample preparation platform was
presented in Baier et al. 2009 [13]. The new data we present
hererefersspeciﬁcallytothetestingofclinicalsamplesonthe
platform.
For evaluation of the sample preparation and nucleic
acid extraction chip, cervical smear specimens collected in
PreservCyt solution from 20 diﬀerent patients were analysed.
The HPV status of these specimens was as follows; HPV16
(n = 13), HPV33 (n = 3), coinfection HPV 16/33 and or 18
(n = 2), and negative (n = 2). From these 20 specimens
a total of 28 extractions were performed to conﬁrm the
reproducibility of the system. Nucleic acid extracts from the
sample preparation chip were then tested using the PreTect
HPV-Proofer. We tested a range of nucleic acid extract
dilutions,(1:1,1:5and1:10).Overall,thedetectionratefor
HPV obtained across all dilutions ranged from 50 to 85.7%.
We did not observe a consistent pattern of ampliﬁcation at
any one dilution.
A subset of samples extracted on the sample preparation
chip platform (n = 6) were chosen for complete validation
on the NASBA chip platform using the criteria described in
Section 2.
3.4. “Proof of Principle”: The NASBA Chip Platform. The
preliminary sensitivity data generated on an earlier version
of the NASBA chip platform showed detection limit of
20 cells/µL for the SiHa cell line, which is comparable to
the performance of PreTect HPV-Proofer [23]. The data
we present here refers speciﬁcally to the testing of clinical
samples on the NASBA chip platform which were processed
for nucleic acids using the sample preparation platform.
In total, 16 NASBA chips were run using 6 clinical
samples to evaluate reproducibility and to compare with
PreTect HPV-Proofer as described above. All of the clinical
specimens which ampliﬁed on PreTect HPV-Proofer did
show positive ampliﬁcation on NASBA chip (Table 1)i no n e
or more dilutions of the TNA from the sample preparation
platform.
Dilution ofthenucleicacidextract1:10yieldedagreater
number of positive results on the NASBA chip than the
undiluted extract and of the channels which ﬁlled correctly
with the 1:10 dilution of extract, 69% were positive on the
NASBA chip, compared with 37.7% of the channels correctly
ﬁlled with the 1:5 dilution of extract. In 4 of the 6 samples
tested, 100% ampliﬁcation for HPV 16 or 33 was obtained
at the 1:10 dilution for channels that ﬁlled correctly. An
example of a positive ampliﬁcation plot and ﬂuorescent
micrograph can be seen in Figure 3.8 Journal of Oncology
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Figure 4: Two colour detection of ﬂuorescence from NASBA ampliﬁed products using the Multiplex Detector Version 2 (a) Detection of
HPV 16-FAM and U1A-ROX, Channels 1, 5, and 6 were empty. (b) Detection of HPV 18-ROX and HPV 31-FAM, Channel 2 empty. (c)
Detection of HPV 33-FAM and HPV 45-ROX, Channels 4 and 8 empty.
3.5. Further Developments towards a “Sample-In Answer-Out”
Platform for Nucleic Acid Extraction and Ampliﬁcation Using
Freeze-Dried Reagents and Duplex Fluorescent Detection. The
ﬂuorescent reader used in this study has been developed
further since the establishment of proof of principle on
clinical specimens. Firstly, the ﬂuorescent reader has been
improved to detect multiple colours (Multiplex Detector
Version 2). Detection of a second ﬂuorescent colour doubles
the number targets which can be identiﬁed on a single
sample. Its performance was evaluated using the PreTectJournal of Oncology 9
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Figure 5: U1A and HPV16 ampliﬁcation plots from NASBA chips containing freeze-dried reagents. Freeze-dried primers and probes
(U1A/HPV16) were deposited in reaction chamber 1 (250nL) and enzymes were deposited in reaction chamber 2 (125nL). Incubation
time in reaction chamber 1 was 5 minutes. The chips were stored at room temperature for 8 and 9 days. (a) Positive control U1A/HPV 16.
Channel 8 was empty. (b) CaSki (1:10 dilution, equivalent to 370 cell/reaction chamber on chip). Channel 6 was empty. (c) HPV 16 positive
clinical specimen (Pretoria). (d) No template control. Channel 7 was empty.
HPV-Proofer positive controls (Primer/Probe Mix: U1A-
ROX, HPV16-FAM), (Primer/Probe Mix: HPV18-ROX,
31-FAM), (Primer/Probe Mix: HPV 33-FAM, 45-ROX),
Figure 4. Acceptable sensitivity of the duplex detection was
achieved and it is comparable with uniplex ampliﬁcation.
In a second further development, some of the NASBA
reagents were integrated into the NASBA chip. This was
achieved by freeze drying of primer and probes and enzyme
mixontothechipasshortlydescribedinmaterialsandmeth-
ods, a comprehensive description is published elsewhere
[26]. For this experiment, we tested 4 chips including an
HPV16/U1A positive control, CaSki cell mRNA, mRNA
extracted from an HPV16 positive clinical specimen (from
Pretoria Hospital) and a no template control (Figure 5). All
channels which ﬁlled with reaction mix were positive for
U 1 Aa n dH P V 1 6 .T h en ot e m p l a t ec o n t r o lw a sn e g a t i v e
(Figure 5). Initial experiments have demonstrated that freeze
dried enzymes can be stored on chip at room temperature
with no loss of stability for at least 1 month (Figure 6).
4. Discussion
This paper demonstrates the utility of a sample preparation
microﬂuidic LOC device and associated instrument and a
NASBA-based ampliﬁcation chip with optical readers for10 Journal of Oncology
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Figure 6: Ampliﬁcation plot of HPV16 and U1A performed on
the NASBA chip with freeze-dried enzymes in reaction chamber 2
stored at room temperature for 32 days. Channel 1 was empty. An
instrumental error resulted in an outlier measurement for HPV16
in channel 5 after 88 minutes.
sequential nucleic acid extraction and NASBA ampliﬁcation
of clinical material. The sample preparation device and a
detailed description of the NASBA chip and reader has
been described previously by the group [13, 24]. However,
this paper describes further progress towards a “sample-in,
answer-out” integrated microﬂuidic system tested on clinical
samples. The proof of principle test identiﬁes the challenges
that must be overcome to achieve a fully integrated walk-
away LOC system and demonstrates its potential utility with
viscous and multicellular clinical specimens in a methanol-
based cytology medium (PreservCyt).
This development of a “sample-in, answer-out” chip
achieves many of the goals of miniaturised LOC approaches
and has the potential to oﬀer a minimal handling, walk-
away lab environment at an aﬀordable price. In terms of the
LOC environment, our approach to developing a “sample-
in, answer-out” system has several potential commercial
outcomes: including separate extraction and ampliﬁcation
on disposable chips, uniﬁed extraction and ampliﬁcation,
and an adaptable NASBA ampliﬁcation platform for use in
a range of disease analyses.
The development of a fully functional integrated LOC
microﬂuidic system that can perform cell lysis, nucleic
acid extraction ampliﬁcation, and detection with on-chip
reagents is still a great challenge [2]; however, discrete exa-
m p l e so fs u b f u n c t i o n so fac o m p l e t es y s t e mh a v eb e e nd e m -
onstrated in chip format over the last number of years
and tested predominantly with cell line material, bacterial
cultures, whole blood, or saliva specimens [27–30].
We have previously demonstrated successful ampliﬁca-
tion of the HPV targets of CaSki, HeLa, and MS751 HPV
positive cell line mRNA prepared by the sample preparation
platform to a detection limit of 5 cells, 5 cells and 50 cells,
respectively, by PreTect HPV-Proofer [13]. In the present
study,20clinicalPreservCytspecimenswereprocessedbythe
sample preparation platform and the performance of the
combined sample preparation and NASBA ampliﬁcation
system was observed. The heterogeneity and varied cellular
component of the test set of cervical PreservCyt specimens
posed a serious challenge. To overcome this, an algorithm
was developed in the LabView software to allow sequential
loading of the cellular material to the cell capture ﬁlter
membrane for cell lysis. For successful ampliﬁcation of the
nucleic acid extracted by the sample preparation device,
dilution was necessary. The extraction chip produced nucleic
acidofadequatequalityforampliﬁcationintheNASBAreac-
tion, with a detection rate of between 50–85%, depending on
dilutionoftheextractfromtheLOCdevice.Therequirement
to dilute the eluate for successful NASBA following removal
from the chip would indicate impurities in the nucleic acid
preparation most likely related to incomplete evaporation
of ethanol containing buﬀer from the SPE matrix and/or
the retention of chaotropic salts from the lysis buﬀer on the
membrane. Examples of this were samples 479 (HPV33+)
and522(HPV16+)whichachievedampliﬁcationinallchan-
nels at the 1:10 dilution but at the 1:5 gave 8 indeterminate
results for HPV33 and 60% successful ampliﬁcation for
HPV16 at the 1:5 dilution, respectively. The requirement
to dilute the nucleic acid was completely dependent on the
quality of the individual sample extract, with one sam-
ple amplifying equally well at the 1:5 as at the 1:10
dilution (Sample 508: HPV33) and another sample giving
consistently bad results at either dilution. Many studies
including those describing LOC devices have highlighted
the ampliﬁcation problems associated with contaminating
ethanol and salts [27, 28].
In this study, 16 NASBA chips were used to amplify
nucleic acid from 6 specimens processed by the sample prep-
aration platform which achieved positive ampliﬁcation by
PreTect HPV-Proofer and 9 NASBA chips were used in the
optimisation of the freeze-dried reagents on control oligos.
WehavedescribedpreviouslythedevelopmentoftheNASBA
platform [24] but have not demonstrated its capacity to am-
plify nucleic acids from either the sample preparation plat-
form or clinical specimens until now. Overall, ampliﬁcation
eﬃciency for the NASBA chip was 69% (based on the num-
ber of positive reactions per channels ﬁlled on the chip),
whilethe number of channels on the chips thatﬁlled correct-
lywas79.7%(premixedreagents).Itisimportanttonotethat
positive ampliﬁcation of HPV mRNA was observed for each
of the 6 clinical specimens tested. Ampliﬁcation failure on
chip, in channels that ﬁlled correctly, can be due to several
reasons including: transfer of NASBA inhibitors from extrac-
tion chip elute and surface coating issues that result in a
nonhydrophilic surface for NASBA reaction.
Incomplete ﬁlling of ampliﬁcation channels can result
from failure of ﬂuid progression through the microﬂuidic
channel and clogging of the reaction channel at a num-
ber of critical stages in the chip assembly, including the
bonding manufacturing process, bubble formation, the valveJournal of Oncology 11
spotting procedure resulting in Teﬂon overﬂow, during the
current manual sealing process or during the manual chip
preparation process which involves application of a thin
layer of grease to the chip to create an airtight seal between
the chip and the instrument. The issue of Teﬂon overﬂow
was a serious challenge and has since been eliminated
by improving the spotting procedures, spotting accuracy,
using more favourable valve geometry, and by optimizing
concentrations of the hydrophobic valve solution [20]. It is
not unlikely that the manual chip preparation procedures as
well as the prototype nature of the instruments contribute
to the observed malfunctions, and it should be possible to
eliminate this by improving the chip fabrication and the
ﬂuidic interface between the instrument and the chip. It
is important to note that the microﬂuidic yield of 79.7%
(NASBA chips with premixed reaction mixture) and 83.3%
(NASBA chips containing freeze dried reagents) is a highly
encouragingresult,especiallytakingintoaccountthecurrent
manual procedures of lamination foil preparation, sealing
and chip preparation prior to insertion into the instrument.
This is the ﬁrst study to comment on the performance of the
microﬂuidic device that was developed therein on a number
of clinical specimens.
This paper presents predominantly a uniplex ampliﬁca-
tion detection approach. However, to demonstrate multi-
plexing feasibility, two spectrally resolvable dyes FAM and
ROX have been successfully applied for duplex detection
(Figures 4 and 5). Introduction of the duplex detection
on-chip is an important improvement of the platform as
it doubles the number of potential targets to be detected
simultaneously on a single sample. The sensitivity of the
duplex detection of diﬀerent HPV types and testing ampli-
ﬁcation of freeze-dried reagents on-chip are acceptable
and comparable with uniplex ampliﬁcation. Testing for an
increasednumberoftargetsononeandthesamesamplealso
reducesanalysiscosts.Theuseofspeciﬁcallyselectedﬁltersin
the detection device allows separate detection spectra for the
reporter molecules. The optical scanning device is spatially
calibrated, allowing precise localisation of the detection
chamber. Several detectors were originally evaluated and a
detector based on best signal to noise characteristics and
price was chosen.
During the development of the NASBA LOC device,
issues in relation to preloading of reagents (NASBA master
mix,primers,probes,andenzyme)onchipbecameapparent.
In order to achieve preloading of primers, probes, and en-
zyme a freeze-drying approach was adopted. This resulted in
successful ampliﬁcation of HPV16 and U1A in all channels
which achieved sample ﬁlling (Figure 5). We are currently
modifying the formulation of the NASBA master mix to
achieve successful preloading of all reagents on chip. NASBA
reagents such as DMSO and sorbitol not suitable for freeze
drying will be stored on the sample preparation module
as liquid (Figure 2(a)). Additionally, the next step involves
preloading of all primers and probes mixes for the 5 HPV
types and the U1A house keeping gene of the PreTect HPV-
Proofer in the parallel reaction chambers on chip to achieve
a complete “sample-in answer-out” point-of-care diagnostic
platform for HPV.
We have recently adapted the extraction and ampliﬁca-
tion chip for sequential integration. Test structures for chip
to chip interface have been evaluated with promising results.
The operating microﬂuidic principles of the two chips are
diﬀerent; in the sample preparation chip, the sample is
pushed through the chip by pressure driven ﬂow, while for
the NASBA chip, capillary forces and pneumatic pressure are
the actuation principles respectively. To ensure a leak-proof
bond between the two chips, the connection point requires a
gasket and air venting to remove the overpressure generated
in the sample preparation chip before the eluate reaches the
NASBA chip where capillary forces take over the actuation.
5. Conclusion
The current paper describes a substantial advance on the
stateoftheartforpoint-of-careHPVdiagnosticstechnology.
We presented a combined extraction and ampliﬁcation in
a microﬂuidic device consisting of extraction and NASBA
chips. In addition, the adopted NASBA method oﬀers the
unique characteristics of isothermal ampliﬁcation, greatly
simplifying the thermocycling requirements for the system:
eﬀectively allowing a “blackbox” technology to be developed
encompassing ampliﬁcation and detection simultaneously
in a real-time format. The ampliﬁcation eﬃciency of the
prototype NASBA platform has been compared to an
industry gold standard for HPV detection with encouraging
results. By this, we have demonstrated the subcomponents
of a complete integrated in vitro diagnostic system: from
clinical sample input to sample preparation to ampliﬁcation
to detection, thus advancing towards a “sample-in, answer-
out” diagnostic platform.
Finally, the technology platform is not limited to diag-
nostics of cervical precancer and cancer as studied in this
work, but it has enormous potential in the monitoring and
diagnosis of gene activity in areas such as infectious disease,
oncology, immune response to allergens, immunotherapies,
and chemotherapies.
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